Extended Data Table 1. Clinical summary of the 22 t-AML whole genome sequencing cases.
Latency is defined as the time from the original cancer diagnosis to the development of t-AML/t-MDS.
| Age | Median | 56.5 years (26–80) |
|
| ||
| Gender | Male | 36.4% |
| Female | 63.6% | |
|
| ||
| Prior Disease | Breast | 45.5% |
| Non-Hodgkin's Lymphoma | 13.6% | |
| Multiple Sclerosis | 9.1% | |
|
| ||
| Known Previous Treatment | Other | 31.8% |
| Alkylator | 45.5% | |
| Topoisomerase inhibitor | 63.6% | |
| Radiation | 68.2% | |
| Autologous Transplant | 9.1% | |
|
| ||
| Latency | Median | 3.2 years (0.9–13.3) |
|
| ||
| Cytogenetics | complex | 22.7% |
| MLL rearrangement | 22.7% | |
| non-complex non-MLL | 63.6% | |
|
| ||
| % Blasts in the bone marrow | Median | 79% (19–95%) |
|
| ||
| Most intensive t-AML/t-MDS treatment regimen | Allogeneic transplant | 27.3% |
| Myeloablative | 40.9% | |
| Non-myeloablative | 13.6% | |
| Other/unknown | 18.2% | |
|
| ||
| Remisison | Yes | 50% |
| No | 40.9% | |
|
| ||
| Overal Survival | Median | 140.5 days (8–2000) |